Lei Yu1,2, Shinya Tasaki1,2, Julie A Schneider1,2,3, Konstantinos Arfanakis1,4,5, Duc M Duong6, Aliza P Wingo7,8, Thomas S Wingo9,10, Nicola Kearns1, Gregory R J Thatcher11, Nicholas T Seyfried6, Allan I Levey9, Philip L De Jager12,13, David A Bennett1,2. 1. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois. 2. Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois. 3. Department of Pathology, Rush University Medical Center, Chicago, Illinois. 4. Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, Illinois. 5. Department of Biomedical Engineering, Illinois Institute of Technology, Chicago. 6. Department of Biochemistry, Emory University, Atlanta, Georgia. 7. Division of Mental Health, Atlanta Veterans Affairs Medical Center, Decatur, Georgia. 8. Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia. 9. Department of Neurology, Emory University, Atlanta, Georgia. 10. Department of Human Genetics, Emory University, Atlanta, Georgia. 11. Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, Chicago. 12. Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, New York. 13. Cell Circuits Program, Broad Institute, Cambridge, Massachusetts.
Abstract
Importance: Identifying genes and proteins for cognitive resilience (ie, targets that may be associated with slowing or preventing cognitive decline regardless of the presence, number, or combination of common neuropathologic conditions) provides a complementary approach to developing novel therapeutics for the treatment and prevention of Alzheimer disease and related dementias. Objective: To identify proteins associated with cognitive resilience via a proteome-wide association study of the human dorsolateral prefrontal cortex. Design, Setting, and Participants: This study used data from 391 community-dwelling older persons who participated in the Religious Orders Study and the Rush Memory and Aging Project. The Religious Orders Study began enrollment January 1, 1994, and the Rush Memory and Aging Project began enrollment September 1, 1997, and data were collected and analyzed through October 23, 2019. Exposures: Participants had undergone annual detailed clinical examinations, postmortem evaluations, and tandem mass tag proteomics analyses. Main Outcomes and Measures: The outcome of cognitive resilience was defined as a longitudinal change in cognition over time after controlling for common age-related neuropathologic indices, including Alzheimer disease, Lewy bodies, transactive response DNA-binding protein 43, hippocampal sclerosis, infarcts, and vessel diseases. More than 8000 high abundance proteins were quantified from frozen dorsolateral prefrontal cortex tissue using tandem mass tag and liquid chromatography-mass spectrometry. Results: There were 391 participants (273 women); their mean (SD) age was 79.7 (6.7) years at baseline and 89.2 (6.5) years at death. Eight cortical proteins were identified in association with cognitive resilience: a higher level of NRN1 (estimate, 0.140; SE, 0.024; P = 7.35 × 10-9), ACTN4 (estimate, 0.321; SE, 0.065; P = 9.94 × 10-7), EPHX4 (estimate, 0.198; SE, 0.042; P = 2.13 × 10-6), RPH3A (estimate, 0.148; SE, 0.031; P = 2.58 × 10-6), SGTB (estimate, 0.211; SE, 0.045; P = 3.28 × 10-6), CPLX1 (estimate, 0.136; SE, 0.029; P = 4.06 × 10-6), and SH3GL1 (estimate, 0.179; SE, 0.039; P = 4.21 × 10-6) and a lower level of UBA1 (estimate, -0.366; SE, 0.076; P = 1.43 × 10-6) were associated with greater resilience. Conclusions and Relevance: These protein signals may represent novel targets for the maintenance of cognition in old age.
Importance: Identifying genes and proteins for cognitive resilience (ie, targets that may be associated with slowing or preventing cognitive decline regardless of the presence, number, or combination of common neuropathologic conditions) provides a complementary approach to developing novel therapeutics for the treatment and prevention of Alzheimer disease and related dementias. Objective: To identify proteins associated with cognitive resilience via a proteome-wide association study of the human dorsolateral prefrontal cortex. Design, Setting, and Participants: This study used data from 391 community-dwelling older persons who participated in the Religious Orders Study and the Rush Memory and Aging Project. The Religious Orders Study began enrollment January 1, 1994, and the Rush Memory and Aging Project began enrollment September 1, 1997, and data were collected and analyzed through October 23, 2019. Exposures: Participants had undergone annual detailed clinical examinations, postmortem evaluations, and tandem mass tag proteomics analyses. Main Outcomes and Measures: The outcome of cognitive resilience was defined as a longitudinal change in cognition over time after controlling for common age-related neuropathologic indices, including Alzheimer disease, Lewy bodies, transactive response DNA-binding protein 43, hippocampal sclerosis, infarcts, and vessel diseases. More than 8000 high abundance proteins were quantified from frozen dorsolateral prefrontal cortex tissue using tandem mass tag and liquid chromatography-mass spectrometry. Results: There were 391 participants (273 women); their mean (SD) age was 79.7 (6.7) years at baseline and 89.2 (6.5) years at death. Eight cortical proteins were identified in association with cognitive resilience: a higher level of NRN1 (estimate, 0.140; SE, 0.024; P = 7.35 × 10-9), ACTN4 (estimate, 0.321; SE, 0.065; P = 9.94 × 10-7), EPHX4 (estimate, 0.198; SE, 0.042; P = 2.13 × 10-6), RPH3A (estimate, 0.148; SE, 0.031; P = 2.58 × 10-6), SGTB (estimate, 0.211; SE, 0.045; P = 3.28 × 10-6), CPLX1 (estimate, 0.136; SE, 0.029; P = 4.06 × 10-6), and SH3GL1 (estimate, 0.179; SE, 0.039; P = 4.21 × 10-6) and a lower level of UBA1 (estimate, -0.366; SE, 0.076; P = 1.43 × 10-6) were associated with greater resilience. Conclusions and Relevance: These protein signals may represent novel targets for the maintenance of cognition in old age.
Authors: Lei Yu; Patricia A Boyle; Aliza P Wingo; Jingyun Yang; Tianhao Wang; Aron S Buchman; Thomas S Wingo; Nicholas T Seyfried; Allan I Levey; Philip L De Jager; Julie A Schneider; David A Bennett Journal: Neurology Date: 2021-12-22 Impact factor: 9.910
Authors: Sarah M Neuner; Maria Telpoukhovskaia; Vilas Menon; Kristen M S O'Connell; Timothy J Hohman; Catherine C Kaczorowski Journal: Trends Neurosci Date: 2022-03-17 Impact factor: 16.978
Authors: Zonghua Li; Michael G Heckman; Takahisa Kanekiyo; Yuka A Martens; Gregory S Day; Maria Vassilaki; Chia-Chen Liu; David A Bennett; Ronald C Petersen; Na Zhao; Guojun Bu Journal: Neurology Date: 2022-03-21 Impact factor: 11.800
Authors: Chanond A Nasamran; Anubhav Nikunj Singh Sachan; Jennifer Mott; Yuliya I Kuras; Clemens R Scherzer; Harvard Biomarkers Study; Eugenia Ricciardelli; Kristen Jepsen; Steven D Edland; Kathleen M Fisch; Paula Desplats Journal: Alzheimers Dement (Amst) Date: 2021-02-20
Authors: Hazal Haytural; Rui Benfeitas; Sophia Schedin-Weiss; Erika Bereczki; Melinda Rezeli; Richard D Unwin; Xusheng Wang; Eric B Dammer; Erik C B Johnson; Nicholas T Seyfried; Bengt Winblad; Betty M Tijms; Pieter Jelle Visser; Susanne Frykman; Lars O Tjernberg Journal: Sci Data Date: 2021-12-03 Impact factor: 6.444
Authors: Erik C B Johnson; E Kathleen Carter; Eric B Dammer; Duc M Duong; Ekaterina S Gerasimov; Yue Liu; Jiaqi Liu; Ranjita Betarbet; Lingyan Ping; Luming Yin; Geidy E Serrano; Thomas G Beach; Junmin Peng; Philip L De Jager; Vahram Haroutunian; Bin Zhang; Chris Gaiteri; David A Bennett; Marla Gearing; Thomas S Wingo; Aliza P Wingo; James J Lah; Allan I Levey; Nicholas T Seyfried Journal: Nat Neurosci Date: 2022-02-03 Impact factor: 28.771